Navigation Links
Optimer Pharmaceuticals Announces Presentations of Additional Phase 3 Fidaxomicin and Prulifloxacin Data at Upcoming ICAAC Annual Meeting
Date:9/2/2009

SAN DIEGO, Sept. 2 /PRNewswire-FirstCall/ -- Results from studies related to Optimer Pharmaceuticals, Inc.'s (Nasdaq: OPTR) lead developmental product candidates will be presented at the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) to be held at The Moscone Center in San Francisco on September 12-15, 2009.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090413/LA97352LOGO)

    Fidaxomicin abstracts and speakers include:

    "Low Recurrence Rate among Patients with C. difficile Infection (CDI)
    Treated with Fidaxomicin (FDX)"
    Poster Presentation: Yoav Golan, M.D., M.S.
    Monday, September 14, 2009 11:15am-1:15pm Pacific Time
    Presentation number: L1-1639 in Hall B

    "Restriction Endonuclease Analysis (REA) Typing of Clostridium difficile
    in a Phase 3 Treatment Trial of Fidaxomicin vs Vancomycin: Decreased Cure
    Rate for Epidemic BI/NAP1/027 Strain"
    Poster Presentation: Dale N. Gerding, M.D.
    Monday, September 14, 2009 11:15am-1:15pm Pacific Time
    Presentation number: L1-1642 in Hall B

    "Comparative Fidaxomicin Susceptibilities of Isolates Collected at
    Baseline, Failure, and Recurrence from Patients in a Phase III Trial of
    Clostridium difficile Infection (CDI)"
    Poster Presentation: Ellie J. Goldstein, M.D.
    Monday, September 14, 2009 11:15am-1:15pm Pacific Time
    Presentation number: L1-1641 in Hall B

    "Safety of Fidaxomicin Versus Vancomycin in Treatment of Clostridium
    difficile Infection"
    Poster Presentation: Sherwood L. Gorbach, M.D.
    Monday, September 14, 2009 11:15am-1:15pm Pacific Time
    Presentation number: L1-1640 in Hall B

    "Pharmacokinetics/Pharmacodynamics (PK/PD) of Fidaxomicin in Treatment of
    Clostridium difficile Infection (CDI)"
    Poster Presentation: Pam Sears, Ph.D.
    Tuesday, September 15, 2009 9:00am-11:00am Pacific Time
    Presentation number: A1-1949 in Hall D

    "Rifampin, Rifaximin, OPT-80 and Tigecycline Susceptibility of C.
    difficile Strains from Canada and Italy: Rifamycin Resistance Entirely
    Predicted by Rifampin E-test with Divergent Rifamycin Resistance among the
    Two Countries"
    Poster Presentation:  Mark A. Miller, M.D.
    Tuesday, September 15, 2009 9:00am-11:00am Pacific Time
    Presentation number: C2-1958 in Hall D

    "Acquisition and Overgrowth of Vancomycin-Resistant Enterococci in
    Patients Treated with Fidaxomicin (FDX) Versus Vancomycin (VAN) for
    Clostridium difficile Infection"
    Oral Presentation: Curtis J. Donskey, M.D.
    Tuesday, September 15, 2009 10:45am-11:00am Pacific Time
    Presentation number: K-1915 in Room 131

    Prulifloxacin abstracts and speakers include:

    "Prulifloxacin, a New Fluoroquinolone Treatment for Traveler's Diarrhea"
    Poster Presentation: Prof. Robert Steffen, M.D.
    Monday, September 14, 2009 11:15am-1:15pm Pacific Time
    Presentation number: L1-1643 in Hall B

    "Recommended Ulifloxacin (Prulifloxacin) MIC Quality Control Ranges for
    Campylobacter jejuni ATCC 33560 Using a CLSI Multi-Laboratory M23-A3 Study
    Design"
    Poster Presentation: J.M. Streit
    Monday, September 14, 2009 11:15am-1:15pm Pacific Time
    Presentation number: D-1433 in Hall B

About Optimer Pharmaceuticals

Optimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative anti-infective products to treat serious infections and address unmet medical needs. Optimer has two late-stage anti-infective product candidates under development. Fidaxomicin, formerly known as OPT-80, is the only antibiotic therapy currently in Phase 3 worldwide clinical development for Clostridium difficile infection. Prulifloxacin is an antibiotic which has completed two Phase 3 clinical trials for the treatment of travelers' diarrhea, a form of infectious diarrhea. Additional information can be found at http://www.optimerpharma.com.

    Contacts

    Optimer Pharmaceuticals, Inc.
    Christina Donaghy, Corporate Communications Manager
    John D. Prunty, Chief Financial Officer & VP Finance
    858-909-0736

    Porter Novelli Life Sciences
    Jason I. Spark, Vice President
    619-849-6005


'/>"/>
SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Optimer Pharmaceuticals Reports First Quarter 2009 Financial Results
2. Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI
3. Optimer Pharmaceuticals to Present at June 2009 Investor Conferences
4. Optimer Pharmaceuticals to Present at the Canaccord Adams 29th Annual Global Growth Conference
5. Optimer Pharmaceuticals Reports Second Quarter 2009 Financial Results
6. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
7. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
10. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
11. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... ... Parallel 6 , the leading software as a service (SaaS) provider ... Patient Encounter CONSULT module which enables both audio and video telemedicine communication between the ... the CONSULT module, patients and physicians can schedule a face to face virtual patient ...
(Date:6/27/2016)... N.C. (PRWEB) , ... June 27, 2016 , ... ... commercial operations for Amgen, will join the faculty of the University of ... as adjunct professor of strategy and entrepreneurship at UNC Kenan-Flagler, with a focus ...
(Date:6/27/2016)...   Ginkgo Bioworks , a leading organism ... today awarded as one of the World Economic ... most innovative companies. Ginkgo Bioworks is engineering biology ... world in the nutrition, health and consumer goods ... customers including Fortune 500 companies to design microbes ...
(Date:6/24/2016)... 2016 Epic Sciences unveiled a liquid ... to PARP inhibitors by targeting homologous recombination deficiency ... new test has already been incorporated into numerous ... types. Over 230 clinical trials are ... including PARP, ATM, ATR, DNA-PK and WEE-1. Drugs ...
Breaking Biology Technology:
(Date:6/7/2016)... -- Syngrafii Inc. and San Antonio Credit Union (SACU) ... Syngrafii,s patented LongPen™ eSignature "Wet" solution into SACU,s ... in greater convenience for SACU members and operational ... document workflow and compliance requirements. Logo ... Highlights: ...
(Date:6/2/2016)... 2, 2016   The Weather Company , an IBM ... an industry-first capability in which consumers will be able to ... ask questions via voice or text and receive relevant information ... Marketers have long sought an advertising solution that ... be personal, relevant and valuable; and can scale across millions ...
(Date:5/24/2016)... -- Ampronix facilitates superior patient care by providing unparalleled technology to leaders of the ... latest premium product recently added to the range of products distributed by Ampronix. ... ... ... Display- Ampronix News ...
Breaking Biology News(10 mins):